超过80%的晚期卵巢癌患者因复发需要接受二线化疗。目前多项大型随机对照试验表明,对于铂类敏感患者,以铂类为基础的联合化疗,如紫杉醇+卡铂或吉西他滨+卡铂,在有效率及改善生存方面优于铂类单药化疗,可作为首选。而对于铂类耐药患者,无论采用何种化疗,效果均不理想,临床上一般采用不良反应较小、使用方便的单药化疗作为姑息性治疗,联合化疗的价值有待更多随机对照试验证明。 More than 80% of patients with advanced ovarian cancer need second-line chemotherapy for relapse. A number of large randomized controlled trials have shown that platinum-based combination chemotherapy, such as paclitaxel + carboplatin or gemcitabine + carboplatin, is superior to platinum-based chemotherapy in terms of efficacy and improved survival for platinum-responsive patients, Can be preferred. For patients with platinum resistance, no matter what kind of chemotherapy, the effect is not ideal, the clinical use of generally less adverse reactions, easy to use single-drug chemotherapy as palliative treatment, the value of combined chemotherapy to be more randomized controlled trials to prove .